Competitor Analysis: Cancer Vaccines

Publisher: La Merie Publishing
Pages: 179
Format: PDF and Online
Product Line:
Competitor Analysis
Product Code: LMCA0118
Release Date: March of 2014

800.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Cancer Vaccines

The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Projects are listed according to their main antigenic constituents: peptides, recombinant proteins, idiotype antibody, DNA (plasmid, expression vector), RNA, virus-like particles (VLP), dendritic cells, tumor cells (tumor cell lines), microorganism-based and others.

Of the 140 clinical stage cancer vaccines, three were approved and are commercialized in the major pharmaceutical markets with combined 2013 sales of US$ 2,385 mln. Peptides and proteins make out 43% of clinical stage cancer vaccines, followed by dendritic cell and tumor cell (line)-based cancer vaccines with each contributing 15% to the clinical cancer vaccine pipeline. DNA- and RNA-based cancer vaccines maked out 17% of the clinical portfolio.

The report includes a compilation of currently active projects in research and development for prophylaxis and therapy of cancer. In addition, the report lists company-specific R&D pipelines of cancer vaccines. Competitor projects are listed in a tabular format providing information on:
• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: Cancer Vaccines

Table of Contents

1. Cancer Vaccines by Main Composition

  • Peptide-based Cancer Vaccines
  • Protein-based Cancer Vaccines
  • Idiotype Antibody-based Cancer Vaccines
  • DNA-based Cancer Vaccines: naked and virally vectored
  • RNA-based Cancer Vaccines
  • Virus-Like Particle (VLP)-based Cancer Vaccines
  • Dendritic Cell-based Cancer Vaccines
  • Tumor Cell and Tumor Cell Line – based Cancer Vaccines
  • Microorganism-based Cancer Vaccines
  • Other and Not Defined Cancer Vaccines

2.  Corporate Cancer Vaccines R&D Pipelines


Competitor Analysis: Cancer Vaccines

Related Companies

ABIVAX
Activartis
Aduro BioTech
Advanced Cancer Therapeutics
Advaxis
Aeterna Zentaris
Agenus
Antigen Express
ApoVax
Ascend Biopharmaceuticals
Asterias Biotherapeutics
Avax Technologies
Bavarian Nordic
Bellicum Pharmaceuticals
Bharat Biotech
Biocon
BioLife Science
BioNTech
Biontech RNA Pharmaceuticals
Biovest International
Celgene
Celldex Therapeutics
Cellular Biomedicine
CSL
CureVac
Dainippon Sumitomo Pharma
DCPrime
Delta-Vir
Dendreon
Etubics
Galena Biopharma
Genexine
Genticel
GlaxoSmithKline
Gliknik
GlobeImmune
Gradalis
H. Lee Moffitt Cancer Center and Research Institute
Heat Biologics
Icon Genetics
Immatics biotechnologies
Immune Design
Immunicum
ImmunoCellular Therapeutics
ImmunoFrontier
Immunovaccine
Immunovative Therapies
Immutep
Innate Immunotherapeutics
Inovio Pharmaceuticals
ISA Pharmaceuticals
KAEL-GemVax
MabVax
Mayo Clinic
MediGene
Mediolanum
Merck
Merck Serono
Mologen
Momotaro-Gene
NewLink Genetics
Northwest Biotherapeutics
Novartis
NovaRx
Ohio State University Comprehensive Cancer Center
Oncopep
OncoTherapy Science
Oncothyreon
Oncovir
Ono Pharmaceutical
Oryx
Otsuka Pharmaceutical
Oxford BioMedica
PDS Biotechnology
Polynoma
Prima Biomed
Profectus BioSciences
Roche
Scancell
Shanghai Zerun Biotech Co
Shenyang Sunshine Pharmaceutical Co (3SBio)
Shiga University
Shionogi
Sidney Kimmel Comprehensive Cancer Center
Stemline Therapeutics
TapImmune
Targovax
Transgene
Ultimovacs
University Hospital Grenoble
University of Arkansas
Vaccibody
Vaccinex
Vaccinogen
Vaxart
Vaxil Biotherapeutics
VAXIMM
Vaxon Biotech
ViroMed
Xiamen Innovax Biotech
Zensun Sci & Tech Co



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top